24 completed, 5 terminated, 1 unknown, 1 withdrawn. 13 Phase 1, 13 Phase 2, 4 Not applicable, 2 Early Phase 1, 2 Phase 3.
Follow Stage IV Skin Melanoma: new trials by email Literature Review of Stage IV Skin Melanoma trials Research Report on Stage IV Skin Melanoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Rituximab and Hyaluronidase Human in Patients With Advanced Melanoma Undergoing Nivolumab and Ipilimumab Therapy Nivolumab, Rituximab and Hyaluronidase Human, Ipilimumab - Cutaneous Melanoma, Stage III, Cutaneous Melanoma, Stage IV | Phase 2 | Completed | Emory University | 15 | 2019-06-05 | 2026-10-02 |
| Acceptance and Commitment Therapy in Improving Well-Being in Patients With Stage III-IV Cancer and Their Partners Cognitive Behavior Therapy, Quality-of-Life Assessment, Questionnaire Administration - Malignant Female Reproductive System Neoplasm, Malignant Hepatobiliary Neoplasm | Not applicable | Completed | Rutgers, The State University of New Jersey | 14 | 2017-12-06 | 2021-04-08 |
| Trigriluzole With Nivolumab and Pembrolizumab in Treating Patients With Metastatic or Unresectable Solid Malignancies or Lymphoma Enzyme Inhibitor Therapy, Laboratory Biomarker Analysis, Nivolumab - Lymphoma, Metastatic Malignant Solid Neoplasm | Phase 1 | Completed | Rutgers, The State University of New Jersey | 14 | 2017-10-03 | 2023-12-06 |
| Health Care Coach Support in Reducing Acute Care Use and Cost in Patients With Cancer Best Practice, Laboratory Biomarker Analysis, Supportive Care - Acute Myeloid Leukemia, Brain Glioblastoma | Not applicable | Completed | Stanford University | 128 | 2017-08-08 | 2025-01-24 |
| Aldesleukin and Pembrolizumab in Treating Patients With Stage III-IV Melanoma Aldesleukin, Laboratory Biomarker Analysis, Pembrolizumab - Metastatic Melanoma, Stage III Mucosal Melanoma of the Head and Neck | Phase 2 | Terminated | Rutgers, The State University of New Jersey | 10 | 2017-03-21 | 2023-08-03 |
| Pembrolizumab and Imatinib in Patients With Locally Advanced/Metastatic Melanoma With c-KIT Mutation/Amplification Imatinib Mesylate, Laboratory Biomarker Analysis, Pembrolizumab - Stage IIIA Skin Melanoma, Stage IIIB Skin Melanoma | Phase 1 / Phase 2 | Withdrawn | Joanne Jeter | 2016-11-04 | 2018-04-05 | |
| Pembrolizumab and Stereotactic Radiosurgery for Melanoma or Non-Small Cell Lung Cancer Brain Metastases Pembrolizumab, Stereotactic Radiosurgery - Metastatic Malignant Neoplasm in the Brain, Metastatic Melanoma | Phase 1 | Completed | Emory University | 25 | 2016-10-04 | 2026-03-09 |
| SRS and Nivolumab in Treating Patients With Newly Diagnosed Melanoma Metastases in the Brain or Spine Laboratory Biomarker Analysis, Nivolumab, Stereotactic Radiosurgery - Metastatic Malignant Neoplasm in the Brain, Metastatic Malignant Neoplasm in the Spine | Phase 1 | Completed | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 17 | 2016-06-23 | 2021-11-30 |
| A Clinical Trial: Adjuvant Low-dose Ipilimumab + Nivolumab After Resection of Melanoma Macrometastases nivolumab, ipilimumab - Stage IIIC Skin Melanoma, Stage IV Skin Melanoma | Phase 1 / Phase 2 | Completed | Universitair Ziekenhuis Brussel | 56 | 2016-03-01 | 2019-01-24 |
| TLR8 Agonist VTX-2337 and Cyclophosphamide in Treating Patients With Metastatic, Persistent, Recurrent, or Progressive Solid Tumors Cyclophosphamide, Laboratory Biomarker Analysis, Pegfilgrastim - Colorectal Adenocarcinoma, Metastatic Pancreatic Adenocarcinoma | Phase 1 | Terminated | Mayo Clinic | 4 | 2016-02-05 | 2018-09-05 |
| Radiation Therapy and MK-3475 for Patients With Recurrent/Metastatic Head and Neck Cancer, Renal Cell Cancer, Melanoma, and Lung Cancer Radiation Therapy (RT), MK-3475 - Head and Neck Squamous Cell Carcinoma, Metastatic Renal Cell Cancer | Phase 1 | Completed | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | 41 | 2015-02-05 | 2025-05-15 |
| MART-1 Antigen With or Without TLR4 Agonist GLA-SE in Treating Patients With Stage II-IV Melanoma That Has Been Removed by Surgery MART-1 Antigen, TLR4 Agonist GLA-SE, Laboratory Biomarker Analysis - Stage IIA Skin Melanoma, Stage IIB Skin Melanoma | Early Phase 1 | Completed | Mayo Clinic | 23 | 2015-01-27 | 2020-01-14 |
| Aldesleukin Imaging in Viewing Tumor Growth in Patients With Stage IV Melanoma Receiving Ipilimumab or Pembrolizumab Therapy Laboratory Biomarker Analysis, Radionuclide Imaging, Technetium Tc 99 Hydrazinonicotinamide-Tricine-linked Interleukin-2 - Stage IV Skin Melanoma | Early Phase 1 | Completed | Mayo Clinic | 5 | 2014-03-01 | 2019-08-05 |
| Phase II Trial of Stereotactic Body Radiotherapy Followed by Ipilimumab in Treating Patients With Stage IV Melanoma Ipilimumab, Laboratory Biomarker Analysis, Pharmacological Study - Recurrent Melanoma, Stage IV Skin Melanoma | Phase 2 | Terminated | University of Washington | 23 | 2014-03-01 | 2020-02-13 |
| Epacadostat and Vaccine Therapy in Treating Patients With Stage III-IV Melanoma Epacadostat, MELITAC 12.1 Peptide Vaccine - Mucosal Melanoma, Recurrent Melanoma | Phase 2 | Completed | Fred Hutchinson Cancer Center | 11 | 2013-09-13 | 2018-06-08 |
| Intravital Microscopy for Identifying Tumor Vessels in Patients With Stage IA-IV Melanoma That is Being Removed by Surgery Diagnostic Microscopy, Fluorescein Sodium Injection, Laboratory Biomarker Analysis - Recurrent Melanoma, Stage IA Skin Melanoma | Not applicable | Completed | Roswell Park Cancer Institute | 10 | 2013-09-04 | 2020-08-07 |
| Translational Study for BRAFV600 Serum and Plasma Determination in Patients With BRAFV600 Metastatic Melanoma Stage IV Skin Melanoma | Completed | Grupo Español Multidisciplinar de Melanoma | 58 | 2013-04-01 | 2015-05-05 | |
| Vaccine Therapy in Treating Patients With Advanced Stage III-IV Melanoma Recombinant Human Hsp110-gp100 Chaperone Complex Vaccine, Laboratory Biomarker Analysis - Recurrent Melanoma, Stage IIIB Skin Melanoma | Phase 1 | Terminated | Roswell Park Cancer Institute | 10 | 2013-03-26 | 2022-07-22 |
| Vaccine Therapy With or Without Sirolimus in Treating Patients With NY-ESO-1 Expressing Solid Tumors DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Laboratory Biomarker Analysis, Pharmacological Study - Anaplastic Astrocytoma, Anaplastic Oligoastrocytoma | Phase 1 | Completed | Roswell Park Cancer Institute | 18 | 2012-03-01 | 2016-10-04 |
| Study With T-cel Receptor Gene Therapy in Metastatic Melanoma TCR transduced T-cells, Biopsy, Blood taking - Stage IV Skin Melanoma, Eye; Melanoma | Phase 1 / Phase 2 | Unknown | The Netherlands Cancer Institute | 12 | 2012-03-01 | 2018-11-02 |
Showing 20 of 31. Sign in to see all of them.
Melanoma (31) · Carcinoma, Renal Cell (6) · Breast Neoplasms (5) · Carcinoma, Non-Small-Cell Lung (5) · Brain Neoplasms (4) · Colorectal Neoplasms (3) · Lung Neoplasms (3) · Ovarian Neoplasms (3) · Pancreatic Neoplasms (3) · Urinary Bladder Neoplasms (3) · Uveal Melanoma (3) · Astrocytoma (2) · Colonic Neoplasms (2) · Esophageal Neoplasms (2) · Glioblastoma (2)
Neoplasms (31) · Neoplasms by Histologic Type (31) · Neoplasms by Site (31) · Neoplasms, Germ Cell and Embryonal (31) · Neoplasms, Nerve Tissue (31) · Neuroectodermal Tumors (31) · Neuroendocrine Tumors (31) · Nevi and Melanomas (31) · Skin Diseases (31) · Skin Neoplasms (31) · Skin and Connective Tissue Diseases (31) · Lung Diseases (8) · Respiratory Tract Diseases (8) · Respiratory Tract Neoplasms (8) · Thoracic Neoplasms (8)
pembrolizumab (5) · Nivolumab (4) · Bevacizumab (3) · Ipilimumab (3) · Radiosurgery (3) · 2,2-dimethyl-N-(6-oxo-6,7-dihydro-5H-dibenzo(b,d)azepin-7-yl)-N'-(2,2,3,3,3-pentafluoropropyl)malonamide (2) · Disulfides (2) · Immunoglobulin G (2) · MART-1 Antigen (2) · Sirolimus (2) · Sorafenib (2) · aldesleukin (2) · 1,2-diaminocyclohexaneplatinum II citrate (1) · AZD 6244 (1) · Biopsy (1)
National Cancer Institute (NCI) (10) · Mayo Clinic (3) · Roswell Park Cancer Institute (3) · Rutgers, The State University of New Jersey (3) · Emory University (2) · Fred Hutchinson Cancer Center (1) · Grupo Español Multidisciplinar de Melanoma (1) · Joanne Jeter (1) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (1) · Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University (1) · Stanford University (1) · The Netherlands Cancer Institute (1) · Universitair Ziekenhuis Brussel (1) · University of Washington (1) · William Carson (1)
United States (26) · Australia (1) · Belgium (1) · Canada (1) · Netherlands (1) · Spain (1)
Craig Slingluff (2) · Adam Berger, MD (1) · Bart Neyns, MD Phd (1) · Biren Saraiya (1) · Douglas Schwartzentruber (1) · Jennifer Johnson, MD, PhD (1) · Joanne Jeter, MD (1) · John Kane (1) · Joseph Skitzki (1) · Kavita Dhodapkar, MD (1) · Keith Flaherty (1) · Kunle Odunsi (1) · Lawrence Kleinberg (1) · Manali Patel (1)
PMID 21631324, PMID 23248256, PMID 23620404, PMID 24047116, PMID 24817603, PMID 27663515, PMID 32752904, PMID 33955240, PMID 34749008, PMID 35771552, PMID 35780243, PMID 36845705, PMID 39462179, PMID 40132910, PMID 42640721
P30CA015083 (3), P30CA072720 (3), N01CM62206 (2), P30CA008748 (2), P30CA016056 (2), P30CA016058 (2), N01CM00071 (1), N01CM62207 (1), P30CA014599 (1), P30CA015704 (1), P30CA044579 (1), P30CA054174 (1), P30CA138292 (1), R01CA158318 (1), R21CA093071 (1)